General Information |
| Clinical trials phase |
Early Phase 1 |
| Start date (estimated) |
2022-05-30 |
| End date (estimated) |
2026-04-30 |
| Clinical feature |
| Label |
Refractory Myelodysplastic Syndrome |
| Link |
http://purl.obolibrary.org/obo/NCIT_C148362 |
| Description |
Myelodysplastic syndrome that does not respond to treatment. |
|
Administrative Information |
| NCT number |
NCT05371730 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05371730 |
| Source weblink |
https://clinicaltrials.gov/show/NCT05371730 |
| Sponsors |
Nuwacell Biotechnologies Co., Ltd.
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
15 |
